Last reviewed · How we verify

Vancomycin and Tobramycin

Major Extremity Trauma Research Consortium · Phase 3 active Small molecule

Vancomycin and tobramycin are a combination of two antibiotics that work synergistically to inhibit bacterial cell wall synthesis and protein synthesis, respectively, to treat infections in trauma patients.

Vancomycin and tobramycin are a combination of two antibiotics that work synergistically to inhibit bacterial cell wall synthesis and protein synthesis, respectively, to treat infections in trauma patients. Used for Infection prophylaxis and treatment in major extremity trauma, Polymicrobial infections in trauma patients.

At a glance

Generic nameVancomycin and Tobramycin
SponsorMajor Extremity Trauma Research Consortium
Drug classAntibiotic combination (glycopeptide + aminoglycoside)
TargetBacterial cell wall (vancomycin) and 30S ribosomal subunit (tobramycin)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Trauma Surgery
PhasePhase 3

Mechanism of action

Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, while tobramycin is an aminoglycoside that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Together, they provide broad-spectrum coverage against gram-positive and gram-negative organisms commonly encountered in major trauma and extremity injuries.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results